206 related articles for article (PubMed ID: 21982163)
1. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T.
Grabner G; Nöbauer I; Elandt K; Kronnerwetter C; Woehrer A; Marosi C; Prayer D; Trattnig S; Preusser M
Magn Reson Imaging; 2012 Jan; 30(1):139-47. PubMed ID: 21982163
[TBL] [Abstract][Full Text] [Related]
2. Fractal analysis of the susceptibility weighted imaging patterns in malignant brain tumors during antiangiogenic treatment: technical report on four cases serially imaged by 7 T magnetic resonance during a period of four weeks.
Di Ieva A; Matula C; Grizzi F; Grabner G; Trattnig S; Tschabitscher M
World Neurosurg; 2012; 77(5-6):785.e11-21. PubMed ID: 22120276
[TBL] [Abstract][Full Text] [Related]
3. Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment.
Yamasaki F; Kurisu K; Aoki T; Yamanaka M; Kajiwara Y; Watanabe Y; Takayasu T; Akiyama Y; Sugiyama K
Eur J Radiol; 2012 Oct; 81(10):2805-10. PubMed ID: 22100373
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab as salvage therapy for progressive brain stem gliomas.
Reithmeier T; Lopez WO; Spehl TS; Nguyen T; Mader I; Nikkhah G; Pinsker MO
Clin Neurol Neurosurg; 2013 Feb; 115(2):165-9. PubMed ID: 22652237
[TBL] [Abstract][Full Text] [Related]
6. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
Takano S; Mashiko R; Osuka S; Ishikawa E; Ohneda O; Matsumura A
Brain Tumor Pathol; 2010 Oct; 27(2):89-94. PubMed ID: 21046310
[TBL] [Abstract][Full Text] [Related]
7. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
8. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
10. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study.
Artzi M; Bokstein F; Blumenthal DT; Aizenstein O; Liberman G; Corn BW; Ben Bashat D
Eur J Radiol; 2014 Jul; 83(7):1250-1256. PubMed ID: 24809637
[TBL] [Abstract][Full Text] [Related]
11. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of serial MRI and histological findings following intra-tumor local chemotherapy for malignant brain tumor].
Shimura T; Nakazawa S; Takahashi H; Node Y; Tamai J; Kumazaki T
Gan To Kagaku Ryoho; 1994 Feb; 21(2):209-18. PubMed ID: 8311491
[TBL] [Abstract][Full Text] [Related]
13. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas.
Hwang EI; Jakacki RI; Fisher MJ; Kilburn LB; Horn M; Vezina G; Rood BR; Packer RJ
Pediatr Blood Cancer; 2013 May; 60(5):776-82. PubMed ID: 22976922
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.
Kothari P; White NS; Farid N; Chung R; Kuperman JM; Girard HM; Shankaranarayanan A; Kesari S; McDonald CR; Dale AM
AJNR Am J Neuroradiol; 2013 Sep; 34(9):1752-1757. PubMed ID: 23578667
[TBL] [Abstract][Full Text] [Related]
16. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Chamberlain MC
Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
[TBL] [Abstract][Full Text] [Related]
17. Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.
Nowosielski M; Wiestler B; Goebel G; Hutterer M; Schlemmer HP; Stockhammer G; Wick W; Bendszus M; Radbruch A
Neurology; 2014 May; 82(19):1684-92. PubMed ID: 24727314
[TBL] [Abstract][Full Text] [Related]
18. Effect of bevacizumab on radiation necrosis of the brain.
Gonzalez J; Kumar AJ; Conrad CA; Levin VA
Int J Radiat Oncol Biol Phys; 2007 Feb; 67(2):323-6. PubMed ID: 17236958
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional susceptibility-weighted imaging at 3 T using various image analysis methods in the estimation of grading intracranial gliomas.
Hori M; Mori H; Aoki S; Abe O; Masumoto T; Kunimatsu S; Ohtomo K; Kabasawa H; Shiraga N; Araki T
Magn Reson Imaging; 2010 May; 28(4):594-8. PubMed ID: 20233645
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab does not increase the risk of remote relapse in malignant glioma.
Wick A; Dörner N; Schäfer N; Hofer S; Heiland S; Schemmer D; Platten M; Weller M; Bendszus M; Wick W
Ann Neurol; 2011 Mar; 69(3):586-92. PubMed ID: 21446027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
